248 related articles for article (PubMed ID: 33371421)
1. Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation.
Gavriilaki E; Sakellari I; Anyfanti P; Batsis I; Vardi A; Bousiou Z; Lazaridis A; Nikolaidou B; Zarifis I; Masmanidou M; Yiannaki E; Markala D; Anagnostopoulos A; Douma S; Gkaliagkousi E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371421
[TBL] [Abstract][Full Text] [Related]
2. A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conventional cardiovascular risk factors.
Gavriilaki E; Anyfanti P; Sakellari I; Batsis I; Dolgyras P; Lazaridis A; Nikolaidou B; Koletsos N; Gavriilaki M; Zarifis I; Masmanidou M; Bousiou Z; Vardi A; Douma S; Anagnostopoulos A; Gkaliagkousi E
Bone Marrow Transplant; 2022 Jan; 57(1):72-77. PubMed ID: 34645924
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
5. Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality.
Sakellari I; Gavriilaki E; Papagiannopoulos S; Gavriilaki M; Batsis I; Mallouri D; Vardi A; Constantinou V; Masmanidou M; Yannaki E; Smias C; Geroukis T; Kazis D; Kimiskidis V; Anagnostopoulos A
J Neurol; 2019 Aug; 266(8):1960-1972. PubMed ID: 31087160
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation.
Leger KJ; Baker KS; Cushing-Haugen KL; Flowers MED; Leisenring WM; Martin PJ; Mendoza JA; Reding KW; Syrjala KL; Lee SJ; Chow EJ
Cancer; 2018 Apr; 124(7):1507-1515. PubMed ID: 29315507
[TBL] [Abstract][Full Text] [Related]
7. Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis.
Eftychidis I; Sakellari I; Anagnostopoulos A; Gavriilaki E
Expert Rev Hematol; 2021 Sep; 14(9):831-840. PubMed ID: 34388057
[TBL] [Abstract][Full Text] [Related]
8. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
11. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
[TBL] [Abstract][Full Text] [Related]
13. Extensive dental caries in patients with oral chronic graft-versus-host disease.
Castellarin P; Stevenson K; Biasotto M; Yuan A; Woo SB; Treister NS
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1573-9. PubMed ID: 22516054
[TBL] [Abstract][Full Text] [Related]
14. Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: a clinical analysis.
Wu Q; Chen H; Fang J; Xie W; Hong M; Xia L
Leuk Res; 2012 Mar; 36(3):275-80. PubMed ID: 21917312
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
17. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS; Kim HT; Costello C; Herrera AF; Locke FL; Maegawa RO; Savell A; Mazzeo M; Anderson A; Boardman AP; Weber A; Avigan D; Chen YB; Nikiforow S; Ho VT; Cutler C; Alyea EP; Bachireddy P; Wu CJ; Ritz J; Streicher H; Ball ED; Bashey A; Soiffer RJ; Armand P
Blood; 2020 Jun; 135(24):2182-2191. PubMed ID: 32478814
[TBL] [Abstract][Full Text] [Related]
19. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
